Summary
Background There are limited data regarding causes of mortality in patients with psoriasis or psoriatic arthritis (PsA) . Objectives This retrospective cohort study evaluated the risk and leading causes of mortality in patients with psoriasis or PsA. Methods Individuals with a hospital-based diagnosis of PsA or psoriasis were identified using the Danish National Patient Registry. Matched control individuals were identified from the general population. The main outcome measures were risk of death and cause-specific mortality in patients with psoriasis or PsA. Results Death rates per 1000 patient-years (with 95% confidence intervals) vs. controls were 22Á3 (19Á7-24Á9) vs. 13Á9 (11Á8-16Á0) for patients with psoriasis and 10Á8 (8Á9-12Á8) vs. 11Á6 (9Á6-13Á6) for patients with PsA. Survival, according to stratified hazard ratios (HRs), was significantly lower in patients with psoriasis than in controls (HR 1Á74, P < 0Á001), but not in patients with PsA (HR 1Á06, P = 0Á19). Significantly increased risk of death was observed in patients with psoriasis vs. controls due to a number of causes; the highest risks were observed for diseases of the digestive system; endocrine, nutritional and metabolic diseases; and certain infectious and parasitic diseases (HRs 3Á61, 3Á02 and 2Á71, respectively). In patients with PsA, increased mortality was observed only for certain infectious and parasitic diseases (HR 2Á80) and diseases of the respiratory system (HR 1Á46). Patients with psoriasis died at a younger age than controls (mean age 71Á0 vs. 74Á5 years, P < 0Á001). Conclusions Patients with severe psoriasis have increased mortality risk compared with matched controls, due to a number of causes. Evidence to support an increased risk for patients with PsA was less convincing.
What's already known about this topic?
• Evidence suggests that patients with psoriasis and psoriatic arthritis (PsA) may have higher rates of comorbidities.
• While an increased risk of mortality has been reported for psoriasis, the evidence is conflicting for PsA.
• There are limited studies exploring cause-specific mortality in psoriasis and PsA.
What does this study add?
• This nationwide population-based cohort study aimed to provide more insight into psoriasis-and PsA-associated mortality.
• This study explored the risks and causes of mortality in patients with a hospitalbased diagnosis of psoriasis or PsA, compared with a matched general population.
• This study demonstrated significantly increased risk of death in patients with psoriasis compared with controls due to a number of causes, but not in patients with PsA vs. controls.
Psoriasis is a chronic inflammatory disease of the skin and joints. It is characterized by erythematous scaly plaques and skin lesions that may be localized or widespread, but are typically found on the elbows, knees and scalp. [1] [2] [3] [4] [5] Peak onset of psoriasis occurs in late adolescence or between the ages of 55 and 60 years. 6 Psoriatic arthritis (PsA) is a form of arthritis that is associated with psoriasis, with patients generally (60-70%) presenting first with psoriasis and being diagnosed later with PsA. [7] [8] [9] PsA is a heterogeneous, chronic inflammatory joint disease associated with joint pain, irreversible joint damage, stiffness, swelling and extra-articular manifestations. [9] [10] [11] [12] [13] [14] [15] Approximately 30% of patients with psoriasis may develop PsA, 10,11 but rates may be higher in patients with more severe psoriasis. 8 Psoriasis and PsA affect up to 11Á4% and 0Á4% of the Western population, respectively. 16, 17 Both psoriasis and PsA are complex diseases that negatively impact patients' quality of life, 3, [18] [19] [20] [21] with psoriasis reported to have a more negative impact on quality of life than other skin conditions (e.g. acne vulgaris or atopic dermatitis). 22 Studies conducted in Europe have shown an association between quality-of-life impairment and visibility of skin lesions and disease activity in psoriasis. 19 Reports also suggest that psoriasis negatively affects social functioning and educational performance. 19, 23 Furthermore, psoriasis is associated with increased healthcare costs and can negatively affect work productivity. Evidence suggests that patients with psoriasis or PsA have higher rates of comorbidities, including cardiovascular disease, arthritis, depression, malignancy, metabolic syndrome, diabetes, obesity and hypertension, than the general population. [24] [25] [26] [27] Age-adjusted retrospective cohort studies have reported that patients with severe psoriasis have an increased risk of mortality compared with patients without psoriasis. 4, 28 This increase in mortality is seen as an increase in all-cause 4,29 and causespecific mortality, with death from cardiovascular diseases being the most common cause. 30 It is unclear whether increased mortality in patients with psoriasis is due to the association between psoriasis and cardiovascular risk factors or whether other factors are at play. [31] [32] [33] The evidence is conflicting as to whether patients with PsA have an increased risk of mortality. [34] [35] [36] This nationwide population-based cohort study was designed to provide more insight into psoriasis-and PsA-associated mortality by exploring the risks and causes of mortality in patients with a hospital-based diagnosis of psoriasis and/or PsA, when compared with a matched general population, using retrospective data from Danish national registries.
Patients and methods

Study design
This observational cohort study was conducted between 1 January 1998 and 31 December 2014. Individuals diagnosed with psoriasis or PsA in a secondary-care setting (i.e. with a hospital-based diagnosis) were identified using data from the Danish National Patient Registry (NPR). The NPR is a comprehensive register with records of all inpatient and outpatient hospital consultations, including International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10) diagnoses. 37, 38 Using the 10-digit personal identification number assigned to all Danish citizens, NPR data can be linked to other nationwide registries, including the Civil Registration System, which has registered deaths and migrations in all Danish citizens. The study was conducted and reported in accordance with the STROBE statement. 39 Permission for data handling and ethical approval were granted by the regional ethics committee and the Danish Data Protection Agency, Copenhagen, Denmark (approval number 2013-54-0410). Informed consent was unnecessary because the study concerned linkage of registry-based data and did not involve handling of patients; an approach that was approved by the ethics committee.
Study population
Eligible patients had a hospital-based diagnosis (ICD-10 code) of psoriasis vulgaris (L40Á0); guttate psoriasis (L40Á4); PsA (L40Á5); other psoriatic arthropathies (L40Á5+), multiple sites (M07Á3); distal interphalangeal psoriatic arthropathy (L40Á5+) (M07Á0); arthritis mutilans (L40Á5+) (M07Á1) or psoriatic spondylitis (L40Á5+) (M07Á2). The populations were drawn at their first contact in the NPR and the index date was the date of first diagnosis; patients with start dates before 1998 were excluded.
The analysis included two study groups: group 1 comprised patients with psoriasis (L40Á0, L40Á4) and group 2 comprised patients with PsA (L40Á5, M07Á3, M07Á0, M07Á1, M07Á2). Because allocation to these groups was based on patients' index diagnoses (i.e. the patient's first diagnosis of psoriasis or PsA), patients could be allocated to only one of the groups. However, patients in group 1 and group 2 could subsequently be diagnosed with PsA and psoriasis, respectively. Each patient was matched for age, sex, marital status and municipality, with two control individuals identified from the general population using Civil Registration System data. The index date of the controls matched with those of the corresponding cases, with the cohort followed up until emigration or death, whichever occurred first.
Statistical analyses
Data were summarized using descriptive statistics, with difference in mean person time in years tested using a v 2 -test. Person-time years, representing the number of years that patients and their controls survive in the period, were calculated from the patients' index dates until the end of the study period, death or other reason for leaving the study population. Information on cause of death was available from the database up to 2013; data for 2014 were excluded from the analyses.
Patients who died within the first year (the index year) were excluded due to matched controls not dying within the first year in which the population was set up. Survival was analysed by the Kaplan-Meier method. Survival was also compared using stratified survival analysis. A subanalysis was performed in patients with psoriasis, excluding patients who developed PsA, to assess whether the findings were consistent with those of the overall psoriasis group. Cause of death was categorized based on 25 groups, numbered A01-A24 (Table S1 and Figs S1 and S2; see Supporting Information), as defined by the Health Data Protection Agency, Sundhedsdatastyrelsen. 40 Since 2002, the Automated Classification of Medical Entities, an international standard for coding causes of death that classifies the underlying cause of death according to ICD-10, 41 has been used to register mortality statistics. The classification groups used closely resemble the World Health Organization classification system. Investigators assigned a cause of death for each patient based on the NPR data, with only one cause of death for each patient and control. Groups with fewer than five patients or controls were eliminated due to anonymity requirements. Differences in the cause of death for cases vs. controls were tested using a two-sided Fisher's exact test. Cox proportional hazards models were used to investigate the risk of death over time for each morbidity cause, while controlling for age and sex. Models were tested for proportionality, and, in all but one cause of death, the model had no proportionality problems. A05 for group 1 was not proportional; to correct for this, a time interaction term was included in the model (i.e. case 9 time) and the hazard ratio (HR) reported was for time equal to 10 years.
Absolute risk was defined as the number of deaths per 1000 patient-years. The adjusted excess risk of death was calculated by subtracting the baseline risk of death in the control group from the product of the risk of death in the control group and the age-and sex-adjusted HR for psoriasis from the Cox models. Excess risk was calculated only for causes of death that had significant HR values. Differences in median age at death for all-cause and cause-specific mortality were tested using Wilcoxon rank sum tests. Analyses were performed using SAS, version 9.4 (SAS Institute Inc., Cary, NC, U.S.A.) and Stata, version 11.0 (StataCorp, College Station, TX, U.S.A.).
Results
Baseline demographics and characteristics
There were 12 160 and 9817 patients with a first-time hospital diagnosis who met the inclusion criteria for group 1 (patients with psoriasis) and group 2 (patients with PsA), respectively. These patients were age and sex matched with a corresponding 23 936 and 19 398 controls (Table 1 ). In patients with psoriasis, 13% had a subsequent diagnosis of PsA, and 10% of patients with PsA had a subsequent diagnosis of psoriasis.
The mean ages of the patients were 47Á6 years (psoriasis) and 49Á6 years (PsA). There was a lower proportion of male patients with PsA than with psoriasis (41Á2% vs. 51Á7%). The mean person times were 7Á31 years (psoriasis) and 6Á69 years (PsA). The death rate per 1000 patient-years (95% confidence interval) was higher in patients with psoriasis than in controls [22Á3 (19Á7-24Á9) vs. 13Á9 (11Á8-16Á0)], but it was comparable in patients with PsA vs. controls [11Á6 (9Á6-13Á6) vs. 10Á8 (8Á9-12Á8)].
Mortality in patients with psoriasis and psoriatic arthritis
Survival, as represented using the stratified hazard ratio (SHR), was significantly lower in patients with psoriasis than in controls (SHR 1Á74, P < 0Á001), indicating a 74% increase in mortality risk for individuals with psoriasis vs. controls. However, this result was not seen in patients with PsA (SHR 1Á06, P = 0Á19). Specific causes of death and HRs of death by patient group are shown in Table S2 (see Supporting Information). The most commonly identified cause of death among patients with psoriasis and matched controls was neoplasms, followed by diseases of the circulatory system (Table S2a) . Of the 17 causes of death analysed, there was a statistically significant increased risk of death from 13 of these causes in patients with psoriasis. Mortality risks, as defined by Cox proportional hazard models, were highest for diseases of the digestive system (HR 3Á61) and for endocrine, nutritional and metabolic diseases (HR 3Á02).
The most commonly identified cause of death in patients with PsA and matched control was neoplasms, followed by diseases of the circulatory system (Table S2b ). Risk of death in patients with PsA was significantly increased only for infectious and parasitic diseases (HR 2Á80) and diseases of the respiratory system (HR 1Á46).
The highest absolute and excess risks of death in patients with psoriasis were seen for neoplasms; diseases of the digestive system, circulatory system and respiratory system; and other diseases of the circulatory system (Table 2 ). In patients with PsA, the highest absolute risk of death was seen only for neoplasms, diseases of the circulatory system, other diseases of the circulatory system and diseases of the respiratory system; the excess risk for these diseases was significant only for certain infectious and parasitic diseases and diseases of the respiratory system (Table 2 ).
Survival analysis indicated that patients with psoriasis died at a younger age than controls, as indicated by the plot for patients with psoriasis being shifted to the left compared with matched controls (Fig. 1a) . The mean age at death of patients with psoriasis vs. controls was 71Á0 vs. 74Á5 years (P < 0Á001). A similar trend was not observed for patients with PsA ( Fig. 1b; mean age of death 71Á3 vs. 71Á1 years; P = 0Á68). The median age at death for all causes (Table S3 ; see Supporting Information) shows that, regardless of sex, patients with psoriasis died at a younger age than controls (psoriasis vs. controls: 76 vs. 80 years for women and 69 vs. 74 years for men; both P < 0Á001). While a trend for death at a younger age was observed in patients with psoriasis across most disease categories, the difference was significant only compared with controls for death caused by neoplasms (men only); mental and behavioural disorders; diseases of the nervous system (women), circulatory system (men), respiratory system (women), digestive system and genitourinary system; and death due to unknown causes. Among patients with PsA, the only significant difference in median age at death compared with controls was observed for deaths due to unknown causes (79 vs. 67 years) in women (Table S3) .
Discussion
This retrospective, population-based cohort study evaluated the burden of psoriasis and PsA in terms of mortality in patients diagnosed in a secondary-care setting in a national sample with age-and sex-matched controls during a 17-year period. The study demonstrated a higher mortality rate per 1000 patient-years in patients with psoriasis than in controls, unlike patients with PsA, who had a mortality rate comparable with controls. Similarly, survival as represented using SHRs was significantly lower in patients with psoriasis than in controls (SHR 1Á74, P < 0Á001), but not in patients with PsA vs. controls (SHR 1Á06, P = 0Á19).
Psoriasis was associated with a significantly increased burden of mortality, compared with controls, due to a variety of The mean age at death for patients with psoriasis vs. controls was 71Á0 vs. 74Á5 years (P < 0Á001), and for patients with PsA vs. controls it was 71Á3 vs. 71Á1 (P = 0Á68).
causes (Table S2 ; see Supporting Information); this finding is consistent with earlier studies reporting an increased risk of mortality among patients with psoriasis vs. the general population. 29, 30, 33 In patients with psoriasis, the highest risks, according to the Cox model HRs, were for diseases of the digestive system and endocrine, nutritional and metabolic diseases. Absolute and excess risks in these patients with psoriasis were highest for neoplasms; diseases of the digestive, circulatory and respiratory systems; and other diseases of the circulatory system. These findings are consistent with previous studies demonstrating circulatory system diseases and cancer to be among the leading causes of mortality in patients with severe psoriasis. 30, 42 The current study also showed that more patients with psoriasis than controls died at a younger age, as shown previously. 4, 30 In patients with PsA, a significantly increased risk of mortality compared with controls was observed only due to certain infectious and parasitic diseases and diseases of the respiratory system. The highest absolute risk of death in patients with PsA vs. controls was seen for neoplasms, diseases of the circulatory system (e.g. heart disease), other diseases of the circulatory system (e.g. hypotension) and diseases of the respiratory system, but the excess risk was not significantly increased for these causes. Certain infectious and parasitic diseases showed a modest absolute and excess risk for patients with PsA. No difference was observed for age at death in patients with PsA vs. controls, with the exception of women who died due to unknown causes. Data from a U.K. cohort study demonstrated that patients with PsA did not have an increased risk of mortality compared with matched controls, patients with psoriasis and those with rheumatoid arthritis. 43 While other populationbased cohort studies have failed to demonstrate a higher risk of mortality in patients with PsA, 43, 44 two independent studies demonstrated that patients with PsA have an increased risk of death caused by diseases of the circulatory system and deaths due to suicide. 45, 46 The chronic inflammatory nature of psoriasis is believed to be a key factor contributing to the increased comorbidity risk, with elevated levels of proinflammatory markers (e.g. tumour necrosis factor-a) having an important role in the pathogenesis. [24] [25] [26] [27] This is supported by reports that patients with more severe psoriasis have a higher comorbidity risk than those with mild psoriasis. 8, 27, 47 Patients in the current study were being managed in secondary care and probably had more severe disease than individuals managed in primary care; 31 a higher proportion with psoriasis (13%) went on to develop PsA than that published previously (5Á1% over 20 years). 48 Indeed, a retrospective study by our group, using data from the Danish NPR, showed that psoriasis is associated with a range of comorbidities, most notable to this study being certain infectious and parasitic diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioural disorders; and diseases of the circulatory, respiratory and digestive systems. Other studies have also established that patients with psoriasis have higher comorbidity rates than controls. 27, 32 Patients with PsA have also been reported to have increased rates of comorbidities compared with controls. 26 Another
Danish registry-based cohort study published by our group demonstrated that patients with PsA have significantly more comorbidities -including neoplasms, cardiovascular disease, respiratory diseases, infectious diseases and haematological diseases -than a matched general-population comparator. 49 In the current study, the findings of a modestly increased mortality risk for patients with PsA appear inconsistent with the reports of increased comorbidity in these patients; however, the lack of overwhelming evidence to show an increased mortality risk is consistent with previous studies exploring mortality risk in patients with PsA. [34] [35] [36] The majority of patients (90%) with an initial PsA diagnosis were not diagnosed with hospital-based psoriasis during the study period.
The current study has limitations because of its observational and retrospective nature. The diagnosis of psoriasis or PsA, which was made in a secondary-care setting, was not validated, and potential misclassification of diagnoses of disease may have caused some inaccuracy in the classification of patients with respect to disease status and category. As this study included only patients with a hospital diagnosis of psoriasis or PsA, this probably resulted in a population with more severe disease, which may have inflated the excess risk of death seen among patients with psoriasis. 31, 50 Patients with mild-to-moderate forms of psoriasis or PsA that were not diagnosed in secondary care may have been included in the control group. Some of the data related to the history of the disease may be incomplete as this was an observational study over a long period of time. It is a limitation of the study that data on therapies of the patients were not included. We cannot rule out that the increased mortality of patients with psoriasis was due to therapies and not the disease itself. Finally, the cause of death was assigned by a single investigator (based on NPR data) and this may be considered a limitation. The strengths of this study were an effective use of nationwide databases enabling analysis of data from a large cohort of patients, and an extended duration of follow-up.
Patients with psoriasis and their clinicians need to be aware of the increased mortality risk. Comorbidity burden has clear implications in terms of increasing mortality risk in patients with psoriasis, but the relationship requires further study for patients with PsA. Results from a Danish cohort study that explored treatment of psoriasis-associated cardiovascular comorbidity showed substantial undertreatment of these risk factors. 31 Early recognition and treatment of comorbidities may help to reduce the risk of mortality shown in the current study. Data from this retrospective, population-based cohort study suggest that patients with a hospital-based diagnosis of psoriasis have an increased risk of mortality compared with matched controls due to a number of causes, most notably neoplasms and diseases of the digestive, circulatory and respiratory systems. Increased burden of comorbidity may have implications for the increased risk of mortality in patients with severe psoriasis. Among patients with PsA, the mortality risk was increased only modestly for a limited number of causes.
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Fig S1. Survival after a diagnosis of (a) psoriasis and (b) psoriatic arthritis, compared with controls. Survival in controls, according to stratified hazard ratios, was significantly lower than in patients with psoriasis, but not psoriatic arthritis. Fig S2. Survival after a diagnosis of psoriasis in patients who did not receive a diagnosis of psoriatic arthritis during the study period. When patients who had a subsequent diagnosis of psoriatic arthritis were excluded from the psoriasis group, the findings were seen to be consistent with those of the overall psoriasis group. 
